Structural epitope screening - gain the combined benefits of epitope binning and mapping in one study

Don’t be in the dark about your antibody binding sites.

Antibody screening and binning has been blind - until now.

Get epitope bins AND locations in a single, high-throughput assay for comprehensive screening at the earliest stages of development.

Before you embark on lengthy and pricey engineering and maturation processes, identify your most promising candidates with unimpeachable evidence.  We undertake a detailed structural characterization of your antigen, no matter how large or small, how complex, or how intractable to structural profiling it is (we’re looking at you, integral membrane proteins). Then, we evaluate binding of all of your antibody candidates, up to hundreds at a time, group them into bins, and map the rough location of each bin on the antigen.  

Learn more about our approach and how it might benefit your antibody in our technical brief.

Our approach provides:

Antibody bins and locations on the antigen in one assay - learn why epitope binning via SPR/BLI isn’t enough

Detailed, higher-order structure of your target protein - no matter how big, how complex, or how challenging

Structure-informed binding sites at the earliest stages of antibody development - no more discovery in the dark!

Screening for biologics – get structural epitopes without compromising on the benefits of binning

Ensure epitopic uniqueness, diversity, and accessibility on the target antigen for improved antibody engineering and affinity maturation.

Epitope binning, via techniques like SPR and BLI, is commonly used due to its speed, cost, and throughput - but binning gives no information about epitope location, residue involvement in binding, and target structure. But what if you could pursue a binning assay that gave you bins AND the location of those bins on the epitope - without compromising on the benefits binning provides? Read on to learn about how we enable just that - our high-resolution epitope profiling service provides structural bins so you can pursue structurally-informed antibody development at the earliest stages of discovery. That means no more surprises about epitope location, identity, or diversity (or lack thereof!).

Binning without structure? You're missing out.

Epitope binning is typically used in the early stages of drug development to categorize antibodies by their binding sites. Conventional approaches, like surface plasmon resonance or biolayer inferometry, have a major limitation: they give no information about the actual location or structure of the epitope on the antigen. Additionally, conventional epitope binning relies on a limited set of experimental conditions and may not capture the full range of antibody binding specificities. And without structural information, the interpretation of epitope binning results can be complex and subjective, resulting in inconclusive and failed experiments.

How do we do it?

Our approach puts structure front-and-center - and we're the only technique on the market that provides structural bins for any antigen and antibody panel. We first characterize the higher-order structure of the antigen in detail using our patented, high-resolution protein footprinting platform. Then, we map the general binding site of each antibody, resulting in a map of epitope bins across a 3D structure of your antigen, even if your antigen doesn't have a known structure or can't be crystallized.

Prefer to take it with you?

Submit the form below and we'll send the brief right to your inbox.

And don’t worry, we care about privacy as much as you do - your data are safe with us.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Learn how structure can enhance binning efforts and how it can drive efficiencies further upstream in the antibody development process.

You'll learn about:

Our approach to high-resolution epitope profiling - antigen structure, epitope bins, and mapped bin locations

How we compare with and improve-upon conventional epitope binning via SPR or BLI

Ways to leverage the data for efficiency gains in antibody engineering, affinity maturation, and later development phases

An understanding of how structure can influence and enhance antibody development at the earliest stages


See the technology used by other innovators to streamline biologic development.

We’ve attracted the attention of industry leaders, investors, and clients, including the top pharmaceutical companies and biotechnology firms in the US, and these esteemed institutional partners.

"Unlike other techniques, hydroxyl radical footprinting allows you to see how a protein is moving around in solution. And it’s much faster. It’s extremely useful to any company that wants to engineer the next billion-dollar drug."